MGMT and glioblastoma: MGMT promoter methylation acts as a chemosensitizer in GBM, by reducing its expression, consequently enhancing the cytotoxic effects of alkylating drugs and predicting a favorable outcome in patients who are exposed to alkylating agent chemotherapy in combination with radiotherapy [4], [17].